We recently published a list of 12 Best Global Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its popular diabetes and weight loss medicines, including Wegovy and ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too worried about the upcoming Medicare price negotiations over blockbuster GLP-1 drugs, even though the company still stands with the industry against ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...

Europe's largest pharmaceutical firm, Novo Nordisk, reported fourth-quarter earnings that surpassed analysts' expectations. The company’s shares jumped more than 6% at the market open in Europe ...

Obesity drug maker Novo Nordisk has forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good ...